HC Wainwright Lowers Earnings Estimates for Sutro Biopharma

Sutro Biopharma, Inc. (NASDAQ:STRO) – Analysts at HC Wainwright decreased their Q1 2026 earnings per share estimates for Sutro Biopharma in a report issued on Tuesday, March 24th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($2.53) per share for the quarter, down from their previous forecast of ($1.54). HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2026 earnings at ($2.58) EPS, Q3 2026 earnings at ($2.59) EPS, Q4 2026 earnings at ($2.62) EPS, FY2026 earnings at ($10.32) EPS, FY2027 earnings at ($8.27) EPS, FY2028 earnings at ($8.06) EPS and FY2029 earnings at ($5.63) EPS.

STRO has been the subject of several other research reports. Wedbush reiterated a “neutral” rating and set a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a research report on Tuesday, December 2nd. Truist Financial upgraded shares of Sutro Biopharma to a “strong-buy” rating in a report on Wednesday. Citigroup raised shares of Sutro Biopharma to an “outperform” rating in a research note on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, Citizens Jmp raised Sutro Biopharma from a “market perform” rating to a “market outperform” rating and set a $23.00 price target on the stock in a research note on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.29.

Sutro Biopharma Trading Down 0.3%

Shares of NASDAQ:STRO opened at $23.50 on Thursday. Sutro Biopharma has a 1-year low of $5.23 and a 1-year high of $26.54. The stock has a market capitalization of $199.99 million, a P/E ratio of -0.90 and a beta of 1.47. The business has a 50-day moving average price of $18.61 and a two-hundred day moving average price of $12.76.

Hedge Funds Weigh In On Sutro Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Invesco Ltd. lifted its holdings in shares of Sutro Biopharma by 137.8% in the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after purchasing an additional 53,390 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Sutro Biopharma by 1,052.8% during the first quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock worth $859,000 after buying an additional 1,206,330 shares in the last quarter. Strs Ohio acquired a new stake in Sutro Biopharma in the 1st quarter valued at approximately $99,000. Marshall Wace LLP acquired a new stake in Sutro Biopharma in the 2nd quarter valued at approximately $166,000. Finally, Cerity Partners LLC lifted its stake in Sutro Biopharma by 169.9% in the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after acquiring an additional 66,372 shares in the last quarter. 96.99% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Sutro Biopharma

Here are the key news stories impacting Sutro Biopharma this week:

• Positive Sentiment: Deutsche Bank raised its price target on STRO to $55 (from $51) and kept a Buy rating — a materially higher target that suggests strong upside vs. the current share price and supports bullish investor expectations. Deutsche Bank raises PT to $55
• Positive Sentiment: Wells Fargo upgraded STRO from Equal Weight to Overweight and raised its price target to $27 (from $8), signaling improving institutional sentiment and providing a nearer-term upside anchor for the stock. Wells Fargo upgrade
• Positive Sentiment: HC Wainwright upgraded STRO from Neutral to Buy and raised its target to $28 (from $10). The firm also published FY2030 EPS projections (large negative EPS expected), but maintained a Buy stance and higher target — a supportive signal from a biotech-focused shop. HC Wainwright upgrade HC Wainwright EPS note
• Neutral Sentiment: Short-interest reports for March show anomalous values (reported as 0 shares with NaN changes and 0.0 days-to-cover across different volume baselines). The data appears unreliable or reflects a reporting/clearing event, so its immediate impact on price is unclear. (Multiple internal short-interest notices consolidated)

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.